27-Sep-2021

Triptorelin Market To Surpass US$ 670 Million By 2026 At a CAGR of 5.2% | Extended Application of Triptorelin in Various Treatment Modalities is expected to Drive Market Growth

Among the numerous medications for achieving medical castration, gonadotropin-releasing hormone (GnRH) agonists have a better safety and effectiveness profile than estrogens and anti-androgens. Furthermore, slow-release GnRH agonist formulations provide patients with more flexibility, better quality of life, and ultimately save costs. Prostate cancer usually advances as the level of testosterone in the body rises. Furthermore, testosterone production can be halted through surgical removal of the testicles or long-term pharmaceutical therapy. Triptorelin is a GnRH agonist that works by preventing the tentacles from producing testosterone. This decreases testosterone levels over time, slowing the spread of prostate cancer.

Request Sample Copy of Triptorelin Report @
https://www.coherentmarketinsights.com/insight/request-sample/1963

Luteinising Hormone-Releasing Hormone analogue triptorelin is a decapeptide analogue (LHRH, also called gonadotropin-releasing hormone [GnRH]). Triptorelin is widely used in the palliative treatment of advanced prostate cancer that is hormone dependent.

Moreover, according to National Institute for Health and Care Excellence (NICE), in May 2013, the licensed indications for luteinising hormone-releasing hormone (LHRH) agonist: triptorelin were extended to include two new indications for prostate cancer: first in neoadjuvant treatment before radiotherapy in high-risk localized or locally advanced disease and second in adjuvant treatment to radical prostatectomy in locally advanced disease at high risk of progression. Triptorelin is administrated intramuscularly or subcutaneously.

Additionally, triptorelin is prescribed for the treatment of Central Precocious Puberty in children aged two and up (CPP). In July 2017, U.S. Food and Drug Administration (FDA), approved Arbor Pharmaceuticals’: Triptodur, in pediatric patients with central precocious puberty. The approval comes after a phase 3 clinical trial (Efficacy, Safety, and Pharmacokinetics [PK] of Triptorelin 6-month Formulation in Patients with Central Precocious Puberty), which looked at the effects of triporelin medication on prepubertal luteinizing hormone levels. Study demonstrated a return to pre-pubertal luteinizing hormone (LH) levels in 93% of enrolled patients, with pre-pubertal luteinizing hormone (LH) suppression maintained at 12 months by 98% of patients.

Triptorelin, a GnRH agonist, is a first-line hormonal treatment that has shown efficacy and safety in individuals with non-metastatic or metastatic prostate cancer in clinical trials. Triptorelin is also being explored for a variety of therapy alternatives, which is still in the early stages of clinical trials. For example, GnRH analogue, triptorelin is being studied to analyze their efficacy and safety for HIV-1 reservoir reduction in Antiretroviral Therapy (ART) treated HIV-1 infected patients. According to ClinicalTrials.gov, in May 2018, this study was conducted by Immune System Regulation AB, and currently in phase II clinical stage.

Triptorelin is also being studied to see how Tamoxifen, Letrozole, and Letrozole + Zoledronate affect bone loss in breast cancer patients who are on adjuvant hormone therapy. According to ClinicalTrials.gov, this study was initiated in July 2017 by the National Cancer Institute (NCI), Naples, and is now in phase III clinical trials. Furthermore, with the successful conclusion of this study and the probable launch of new products during the forecast period, the triptorelin market exhibits attractive revenue development in the near future.

Request PDF Report Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/1963

Furthermore, triptorelin’s increased efficacy and effectiveness in suppressing gonadotropin in Central Precocious Puberty (CPP) among young boys and girls is projected to propel the triptorelin market growth. For example, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with CPP from first administration.

In addition, considerable research and development is being done on the use of androgen deprivation therapy with triptorelin to slow the course of salivary gland cancers that express androgen receptors. For example, in January 2016, Debiopharm International SA collaborated with European Organization for Research and Treatment of Cancer (EORTC) to investigate Triptorelin for treatment of salivary gland cancer. Debiopharm International SA will provide a one-month formulation of triptorelin pamoate 3.75 mg to patients with salivary gland cancer who are enrolled in an EORTC-sponsored clinical trial. Researchers will compare the efficacy and safety of androgen chemotherapy with androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor-expressing salivary gland malignancies during the clinical trial.

The rising prevalence of prostate cancer worldwide, as well as the widespread use of triptorelin in prostate cancer treatment to slow the progression of the disease by lowering the amount of testosterone synthesised by the body, are expected to propel the triptorelin market forward during the forecast period.

For example, according to the World Cancer Research Fund (WCRF) International, 2012, over 1.1 million cases of prostate cancer were recorded, accounting for around 8% of all new cancer cases worldwide. Furthermore, the developed economies accounted for roughly 68 percent of prostate cancer incidences. The highest rates of prostate cancer were seen in Oceania and North America, with the lowest rates found in Asia and Africa.

Furthermore, according to Cancer Research UK, roughly 47,151 new cases of prostate cancer were documented in the United Kingdom in 2015. Furthermore, in 2015, prostate cancer accounted for 13% of all cancer cases in the United Kingdom. Prostate cancer was the second-leading cause of cancer deaths among men in the United Kingdom in 2014, accounting for 13% of all male cancer fatalities. In addition, according to the same source, 11,287 guys in the United Kingdom died of prostate cancer in 2014. According to the crude mortality rate, 36 men died of prostate cancer for every 100,000 men in the country.

Key players operating in triptorelin market include Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC.

Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1963

Reasons to Purchase this Report

• Current and future of global Triptorelin market outlook in the developed and emerging markets

• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

• Regions/countries that are expected to witness the fastest growth rates during the forecast period

• The latest developments, market shares, and strategies that are employed by the major market players

Table of Contents

Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
Market Overview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Drug Type
  - Market Snippet, By Application
  - Market Snippet, By Distribution Channel
  - Market Snippet, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Regulatory Scenario
- Market Trends
- Epidemiology
- New Product Approvals/Launch
- Mergers/ Acquisition
- Strategic Collaborations
- PEST Analysis
Global Triptorelin Market, By Drug Type, 2016 – 2026 (US$ Million)
- Introduction
  - Market Share Analysis, 2018 and 2026 (%)
  - Y-o-Y Growth Analysis, 2017 – 2026
  - Segment Trends
- Triptorelin pamoate
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Triptorelin acetate
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Triptorelin embonate
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Global Triptorelin Market, By Application, 2016 – 2026 (US$ Million)
- Introduction
  - Market Share Analysis, 2018 and 2026 (%)
  - Y-o-Y Growth Analysis, 2017 – 2026
  - Segment Trends
- Prostate Cancer
  - Introduction
  - Market Share Analysis, 2018 and 2026 (%)
  - Y-o-Y Growth Analysis, 2017 – 2026
- Radical Prostatectomy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Endometriosis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Salivary Gland Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Central Precocious Puberty
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Global Triptorelin Market, By Distribution Channel, 2016 – 2026 (US$ Million)
- Introduction
  - Market Share Analysis, 2018 and 2026 (%)
  - Y-o-Y Growth Analysis, 2017 – 2026
  - Segment Trends
- Hospital Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Retail Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Online Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Global Triptorelin Market, By Regions, 2016 – 2026 (US$ Million)
- Introduction
  - Market Share Analysis, By Region, 2018 and 2026 (%)
  - Y-o-Y Growth Analysis, For Regions, 2017 – 2026
- North America
  - Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Application, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
    - U.S.
    - Canada
- Europe
  - Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Application, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Application, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
    - China
    - Japan
    - India
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Latin America
  - Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Application, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Africa
  - Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Application, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
    - North Africa
    - Central Africa
    - South Africa
- Middle East
  - Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Application, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
    - GCC Countries
    - Israel
    - Rest of Middle East
Competitive Landscape
- Heat Map Analysis
- Company Profiles
  - Ipsen
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
  - Bachem
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
  - Ferring Pharmaceuticals Pvt Ltd.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
  - Chengdu Tiantaishan pharmaceutical Co., Ltd.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
  - Tecnofarma
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
  - Dr. Reddy’s Laboratories Ltd.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
  - Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.)
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
  - Debiopharm Group
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
  - Arbor Pharmaceuticals, LLC
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Developments/Updates
    - Strategies
- Analyst Views
Section
- References
- Analyst Views
- Research Methodology
- About Us and Sales Contact

Customization of the Report

In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.

Also, Research Report Examines:

• Competitive companies and manufacturers in global market

• By Product Type, Applications & Growth Factors

• Industry Status and Outlook for Major Applications / End Users / Usage Area

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Editor Details

Company:
- CDN Newswire

Last Updated: 27-Sep-2021